1 October 2015 - The October 2015 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. The Schedule inclides the following new and revised listings:

• Aciclovir (AciVision) - new formulation
• Aflibercept (Eylea) - new formulation
• Dapagliflozin propanediol monohydrate with metformin hydrochloride (Xigduo XR) - new indication
• Panitumumab (Vectibix) - new indication
• Testosterone (various presentations) - restriction change
• Tiotropium bromide monohydrate (Spiriva Respimat) - new formulation
• Tofacitinib citrate (Xeljanz) - new listing

For more details, go to: http://www.pbs.gov.au/browse/changes